Author/Authors :
Akkaş, Ebru Atasever Sivas Numune Hastanesi - Radyasyon Onkolojisi Kliniği, Turkey , Yücel, Birsen Cumhuriyet Üniversitesi - Tıp Fakültesi - Radyasyon Onkolojisi Anabilim Dalı, Turkey , Kılıçkap, Saadettin Cumhuriyet Üniversitesi - Tıp Fakültesi - Tıbbi Onkoloji Bilim Dalı, Turkey , Babacan, Nalan Akgül Cumhuriyet Üniversitesi - Tıp Fakültesi - Tıbbi Onkoloji Bilim Dalı, Turkey , Altuntaş, Emine Elif Cumhuriyet Üniversitesi - Tıp Fakültesi - Kulak Burun Boğaz Hastalıkları Anabilim Dalı, Turkey
Abstract :
Aim. Our aim was to investigate the clinicopathological features, the treatment outcome and the prognostic factors affecting survival in patients with head and neck cancer followed and treated in our center. Methods. The demographic, clinical and the histopathological data of the patients who were admitted to our center between 2007 and 2010 with a diagnosis of head and neck cancer were examined using the medical records. Results. The data from 82 patients were analyzed. There were 72 men (88%) and 10 women (12%). The median age of the patients was 57 (20-80) years. The youngest patients had nasopharyngeal, parahypopharyngeal and paranasal sinus tumors. The most commonly encountered malignancy was the laryngeal cancer, which was found in 37 patients (45%). Fifty-five patients (67%) were Eastern Cooperative Oncology Group 1. The most common grade was the locally advanced stage with 51 patients (62%). At time of the diagnosis, 60 (75%) patients had anemia, 30 (60%) patients had an elevated C-reactive protein, and 72 (89%) patients had weight loss. Squamous cell carcinoma, which was seen in 69 (84%) patients, was the most common histological type. Seventeen (47%) patients had perineural invasion, 17 (47%) patients had lymphovascular invasion, and 12 (32%) patients had extracapsular invasion. Among the patients, the most common grade was grade II, which was found in 34 (42%) patients. The overall median survival was 34 months. The 2-year survival rate was 75% for the patients with early-stage (I-II) cancer and 51% for the patients with locally advanced (III-IVA and B) cancer, the median survival was 10 months in the presence of metastatic disease. The presence of hypertension comorbidity, performance status, location and stage of the cancer, T and N stage, interruption of radiation therapy, C-reactive protein levels, and anemia were the factors that determined survival. Conclusion. The presence of hypertension, performance status, location and stage of the cancer, T and N stage, interruption of radiation therapy, C-reactive protein levels, and anemia were identified as prognostic factors affecting survival in patients with head and neck cancers.
NaturalLanguageKeyword :
Head and neck cancer , radiotherapy , chemotherapy , prognosis
